时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
A clinically useful question is whether age and CYP2D6 genotype affect the same pharmacokinetic outcome or different aspects of VEN disposition.；We hypothesized that age would be more strongly associated with VEN/dose, whereas CYP2D6 genotype would be more strongly associated with the ODV/VEN ratio.
方法
The study was approved by Dokkyo Medical University Hospital Ethics Committee for Clinical Trials (approval number: R‐109‐1 J), and written informed consent was waived with an opt‐out opportunity according to the approved protocol.；The TDM and genotyping procedures followed previously reported methods [].；Plasma VEN and ODV concentrations were quantified using high‐performance liquid chromatography with ultraviolet detection and mirtazapine as the internal standard; the assay was based on a published method with local modifications [, ].；No formal statistical test was performed to compare these effect‐size indices directly; therefore, differences in incremental R2 were interpreted descriptively and cautiously.
核心结论
The median age was 48.0 years (IQR, 34.3–63.5; range, 20–84), and 19 patients (24.4%) were aged 65 years or older.；CYP2D6 reduced/no‐function allele counts were 0, 1, and 2 in 36, 28, and 14 patients, respectively (Table ).；Age was positively correlated with VEN/dose (Spearman rho = 0.295, p = 0.0086). ‖ 结论：These findings support integrating TDM, pharmacogenetic information, and geriatric clinical assessment when optimizing VEN treatment in psychiatric practice.
局限
Because no formal statistical comparison between these effect‐size indices was performed, this difference should be interpreted as descriptive and hypothesis‐generating.；Conversely, TDM results without genotype information may not fully explain an unusually low ODV/VEN ratio.；Several limitations should be acknowledged.
对本项目的价值
★☆☆☆☆ 干预证据决定参照标准效应量——任何抗衰干预的收益至少应对标该基线。
全文来源
PMC JATS 全文（正文 13,703 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Distinct Associations of Age and CYP2D6 Genotype With Parent Venlafaxine Exposure and O-Demethylation in Japanese Psychiatric Patients.
- 期刊与标识：Neuropsychopharmacol Rep · PMID 42956830 · DOI 10.1002/npr2.70175
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。